| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers G > Headlines for GlaxoSmithKline plc > News item |
GlaxoSmithKline: study shows effectiveness of Advair plus inhaled corticosteroid in asthma treatment
By Lisa Kerner
Charlotte, N.C., July 21 - GlaxoSmithKline said one of the largest biopsy studies conducted to date shows that a lower dose of an inhaled corticosteroid (ICS) with the addition of a long-acting beta2-agonist (LABA) is as effective in maintaining control of airway inflammation as a medium-dose ICS alone in patients with moderate asthma.
The study compared Advair Diskus (fluticasone propionate and salmeterol) 100/50 mcg with fluticasone propionate (FP) 250 mcg.
In the double-blind, parallel-group study, 88 patients with asthma were randomized to therapy with an ICS alone (FP 250 mcg) or an ICS plus a LABA (Advair 100/50 mcg) twice daily for 24 weeks.
Bronchial biopsies and bronchoalveolar lavage were performed prior to randomization and after the 24-week treatment period.
Both treatments were well-tolerated and no serious drug-related adverse events were reported during the treatment period.
"These findings reinforce an earlier study which shows that adding a LABA to a lower dose ICS is an effective treatment option for maintaining control of asthma," lead study investigator Nizar N. Jarjour said in a company news release.
The study findings are consistent with current National Institute of Health Guidelines for the Diagnosis and Management of Asthma recommendations on the use of an ICS and a LABA as the preferred therapy.
Undertreatment of asthma can lead to frequent symptoms and attacks, activity limitation and a decline in lung function, the release said.
The biopsy study was published in the July issue of the Journal of Allergy and Clinical Immunology.
GlaxoSmithKline is a London-based pharmaceutical company.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.